Less is more? Screening for steatosis in older populations
Hannes Hagström, Ying Shang – 7 July 2022
Mast cells selectively target large cholangiocytes during biliary injury via H2HR‐mediated cAMP/pERK1/2 signaling
Tianhao Zhou, Vik Meadows, Debjyoti Kundu, Konstantina Kyritsi, Travis Owen, Ludovica Ceci, Guido Carpino, Paolo Onori, Eugenio Gaudio, Nan Wu, Shannon Glaser, Burcin Ekser, Gianfranco Alpini, Lindsey Kennedy, Heather Francis – 6 July 2022 – Bile ducts are heterogenous in structure and function, and primary sclerosing cholangitis (PSC) damages specific bile ducts leading to ductular reaction (DR), mast cell (MC) infiltration, increased histamine release, inflammation, and fibrosis.
RNA helicase DEAD‐box protein 5 alleviates nonalcoholic steatohepatitis progression via tethering TSC complex and suppressing mTORC1 signaling
Yanqiu Zhang, Shengtao Ye, Weijia Lu, Jiawen Zhong, Yingrong Leng, Ting Yang, Jun Luo, Wenjun Xu, Hao Zhang, Lingyi Kong – 6 July 2022
The emotional burden of caregiving for patients with cirrhosis
Zachary M. Saleh, Najat E. Salim, Samantha Nikirk, Marina Serper, Elliot B. Tapper – 5 July 2022 – Caregivers for patients with cirrhosis face immense physical and psychological strain that negatively impact quality of life and ability to care for oneself. The aim is to explore the caregiver experience for patients with cirrhosis, identify prominent stressors, and understand the multidimensional contributors to caregiver burden, to help tailor effective interventions.
Essential lipid autacoids rewire mitochondrial energy efficiency in metabolic dysfunction‐associated fatty liver disease
Cristina López‐Vicario, David Sebastián, Mireia Casulleras, Marta Duran‐Güell, Roger Flores‐Costa, Ferran Aguilar, Juan José Lozano, Ingrid W. Zhang, Esther Titos, Jing X. Kang, Antonio Zorzano, Makoto Arita, Joan Clària – 4 July 2022
Letter to the editor: l‐ornithine l‐aspartate in acute treatment of severe hepatic encephalopathy: A double‐blind randomized controlled trial
Alexander J. Kovalic, Tai‐Ping Lee, Ben L. Da – 4 July 2022
Age and the relative importance of liver‐related deaths in nonalcoholic fatty liver disease
Huapeng Lin, Terry Cheuk‐Fung Yip, Xinrong Zhang, Guanlin Li, Yee‐Kit Tse, Vicki Wing‐Ki Hui, Lilian Yan Liang, Jimmy Che‐To Lai, Stephen Lam Chan, Henry Lik‐Yuen Chan, Grace Lai‐Hung Wong, Vincent Wai‐Sun Wong – 4 July 2022
Letter to the editor: Six‐month antibody kinetics and durability in liver transplant recipients after two doses of SARS‐CoV‐2 mRNA vaccination
Amy Chang, Alexandra T. Strauss, Jennifer L. Alejo, Teresa P.‐Y. Chiang, Nicole F. Hernandez, Laura B. Zeiser, Brian J. Boyarsky, Robin K. Avery, Aaron A. R. Tobian, Macey L. Levan, Daniel S. Warren, Jacqueline M. Garonzik‐Wang, Allan B. Massie, William A. Werbel, Dorry L. Segev – 4 July 2022
Ranking of transarterial and targeted therapies for advanced hepatocellular carcinoma in the era of immuno‐oncology: A network meta‐analysis of randomized sorafenib‐controlled trials
Jihyun An, Seungbong Han, Ha Il Kim, Ju Hyun Shim – 3 July 2022 – To date, no studies have compared the new first‐line atezolizumab+bevacizumab with transarterial therapies combined with the prior standard‐of‐care, sorafenib, in patients with advanced hepatocellular carcinoma (HCC). We compared and ranked all relevant transarterial and targeted treatments competing with atezolizumab+bevacizumab for such disease, based on direct and indirect evidence.